Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer's Drug
How many members of the FDA advisory committee voted in favor of the experimental Alzheimer’s drug?
All 11 members of the FDA advisory committee voted in favor of the experimental Alzheimer's drug, donanemab, stating that its benefits outweigh the risks2.
How did the FDA advisory committee justify the approval of donanemab despite its safety risks?
The FDA advisory committee justified the approval of donanemab despite its safety risks because the benefits of the drug were found to outweigh the risks for people with early stages of Alzheimer's disease. The committee acknowledged that Alzheimer's is a devastating disease with no cure, and even a modest benefit from the drug could be valuable for patients. The drug, donanemab, has shown in studies to slow cognitive decline in patients in the early stages of Alzheimer's.
What pharmaceutical company is responsible for the development of donanemab?
Eli Lilly is the pharmaceutical company responsible for the development of donanemab, an experimental drug for Alzheimer's disease.